Dana-Farber/Mass General Brigham Cancer Care, Inc.
Welcome,         Profile    Billing    Logout  
 0 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Frigault, Matthew J
NCT06550141: Emapalumab Prevention of CAR-T Cell Associated Toxicities

Not yet recruiting
2
28
US
Emapalumab, Human anti-interferon gamma (IFNγ) monoclonal antibody, Gamifant, Cyclophosphamide, Fludarabine Phosphate, Axicabtagene Ciloleucel
Marcela V. Maus, M.D.,Ph.D., Swedish Orphan Biovitrum
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
08/26
08/27
NCT05952804: IVIG for Infection Prevention After CAR-T-Cell Therapy

Recruiting
2
150
US
Immune Globulin Infusion (Human), 10% Solution, GAMMAGARD LIQUID, Anti-CD19 CAR T Cells Preparation, CD19-targeting CAR-T Cells, Saline, 7647-14-5, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Survey Administration, Electronic Health Record Review
Fred Hutchinson Cancer Center, Takeda, National Cancer Institute (NCI)
Lymphoma
07/27
07/28
NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated
1/2
13
US
GDA-201, NAM NK
Gamida Cell ltd
Non-Hodgkin Lymphoma
04/24
04/24
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
NCT04134117: Tisagenlecleucel in Primary CNS Lymphoma

Completed
1
6
US
Tisagenlecleucel, KYMRIAH
Matthew J. Frigault, M.D., Novartis
Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
04/22
04/22
NCT04136275: CAR-37 T Cells In Hematologic Malignancies

Completed
1
6
US
CAR-37 T cells
Marcela V. Maus, M.D.,Ph.D.
Hematologic Malignancy, Leukemia, Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin
09/23
03/24
NCT05020444: TriPRIL CAR T Cells in Multiple Myeloma

Recruiting
1
18
US
TriPRIL CAR T Cells, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludara
Marcela V. Maus, M.D.,Ph.D.
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
01/26
01/28
ARC-101, NCT04155749: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Active, not recruiting
1
40
US
anitocabtagene-autoleucel
Kite, A Gilead Company, Arcellx, Inc.
Relapsed and Refractory Multiple Myeloma
08/24
11/35
NCT06026319: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Recruiting
1
24
US
CD79b-19 CAR T cells, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludara
Marcela V. Maus, M.D.,Ph.D.
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Grade 3b Follicular Lymphoma, Mantle Cell Lymphoma
01/27
01/28
NCT04473937: Radiation Post-CAR T in Refractory Lymphoma

Terminated
N/A
3
US
Radiotherapy
Massachusetts General Hospital
Hematologic Malignancy, Refractory Lymphoma
10/21
07/23
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT05024175: Long-term Follow-up of Subjects Treated with CAR T Cells

Recruiting
N/A
45
US
Disease assessments, Tumor Biopsy, Blood test
Massachusetts General Hospital
Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
08/38
08/39

Download Options